We have the pleasure to announce that the French Ministry of Higher Education & Research has recently awarded the CIR accreditation to GenomeScan. Crédit d’Impôt Recherche (CIR), or Research Tax Credit (RTC), is a tax incentive designed to promote innovation and competitiveness in companies, through R&D projects. If your company is in France or is liable for income tax in France, you can now qualify for a tax credit for the projects you outsource to GenomeScan.
The purpose of the Crédit d’Impôt Recherche is to encourage companies to engage in research and development (R&D) activities. The CIR level varies according to the geographical location of the company.
dr. Stefanie Klaver-Flores, BU oncology manager commented:
“We are excited to announce that we have received accreditation, enabling our current and future customers in France to avail themselves of tax relief on their R&D expenditures dedicated to GenomeScan. This accreditation marks a significant step forward in our commitment to providing valuable benefits to our clients while fostering innovation in the field.”
Tax credit benefits possible with GenomeScan
GenomeScan obtained CIR accreditation currently covering 2023, 2024, and 2025. This means our French customers can apply for benefits retrospectively. We will also consider the renewal of our Crédit d’Impôt Recherche accreditation at the end of each accreditation period, continuing to support our customers in France in their R&D activities.
- Currently covering the years 2023, 2024, 2025.
- Tax credit amounting up to 30% of all R&D expenses.
You can learn more about the qualification criteria and conditions here.
About GenomeScan
GenomeScan is a multi-omics solution provider utilizing state-of-the-art technologies including Next Generation Sequencing (NGS). GenomeScan offers customizable solutions to pharmaceutical and biotechnology companies, healthcare providers, and academic institutions. Our service portfolio covers DNA, RNA, and epigenetics sequencing, as well as proteomics analysis with applications ranging from early discovery and preclinical drug development to clinical trials and manufacturing.
Our 15+ years of experience in the industry, in-house expertise in oncology and genetic QC, and robust bioinformatics pipelines let us stand out with the quality of our services. Additionally, short turnaround times and workflows that adhere to ISO/IEC 17025, ISO15189 and GCLP guidelines help you advance in your development programs with confidence.
